 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
47 News |  |
| «12 |
- | ethacrynic acid / Generic mfg., cisplatin / Generic mfg.
Journal: Bis-conjugation of Bioactive Molecules to Cisplatin-like Complexes through (2,2'-Bipyridine)-4,4'-Dicarboxylic Acid with Optimal Cytotoxicity Profile Provided by the Combination Ethacrynic Acid/Flurbiprofen. (Pubmed Central) - Feb 23, 2021
In particular, the combination of ethacrynic acid and flurbiprofen in 3 overcomes cisplatin-based resistance and provides strong cancer cell selectivity. Enzyme inhibition assays on human GST P1 and human COX-2 and cross-experiments with complex 1, analogous to 2-4 but lacking bio-groups, revealed a clear synergy between the Pt frame and the bioactive organic components.
- | ethacrynic acid / Generic mfg.
Journal: Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug. (Pubmed Central) - Jan 29, 2021
The most important result of this analysis is the demonstration that ethacrynic acid, a powerful diuretic, is revealed to be an effective inhibitor of SARS-CoV-2 main protease. Even with all the necessary cautions, given the particular nature of this drug, these data can be the starting point for the development of an effective therapeutic strategy against SARS-CoV-2.
- | Invirase (saquinavir) / Roche
Preclinical, Journal: Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. (Pubmed Central) - Jan 21, 2021
Ethacrynic acid, naproxen, allopurinol, butenafine hydrochloride, raloxifene hydrochloride, tranylcypromine hydrochloride, and saquinavir mesylate have been found to block the proteolytic activity of SARS-CoV-2 3CLpro. The inhibitory activity of these repurposing drugs against SARS-CoV-2 3CLpro highlights their therapeutic potential for treating COVID-19 and other Betacoronavirus infections.
- || Henletor (torsemide) / Orchid
Clinical, Journal: Loop Diuretics: Clinical Application Information for Nephrology Nurses and Practitioners. (Pubmed Central) - Jan 15, 2021
Loop diuretics are routinely used for many clinical indications, and nephrology practitioners are well informed in the management of their use in daily practice. This article highlights key information on the most commonly used loop diuretics (e.g., furosemide and torsemide) and provides important clinical features related to pharmacokinetics properties, dosing consideration, route of administration, side effects, and other considerations for practitioners.
- | Trial completion date: ACEI or ARB and COVID-19 Severity and Mortality in US Veterans (clinicaltrials.gov) - Nov 3, 2020
P=N/A, N=10000, Active, not recruiting, Sponsor: University of Utah
This article highlights key information on the most commonly used loop diuretics (e.g., furosemide and torsemide) and provides important clinical features related to pharmacokinetics properties, dosing consideration, route of administration, side effects, and other considerations for practitioners. Trial completion date: Jul 2020 --> Dec 2020
- | New trial: ACEI or ARB and COVID-19 Severity and Mortality in US Veterans (clinicaltrials.gov) - Jul 13, 2020
P, N=10000, Active, not recruiting, Sponsor: University of Utah
- | Edecrin (ethacrynic acid) / Bausch Health
Journal: Mapping glutathione utilization in the developing zebrafish (Danio rerio) embryo. (Pubmed Central) - Mar 2, 2020
MCB staining was then applied to test for GSH disruptions caused by the toxicants perfluorooctanesulfonic acid and mono-(2-ethyl-hexyl)phthalate; MCB fluorescence responded in a dose, structure and age-dependent manner. MCB staining is a robust, sensitive method to detect spatiotemporal changes in GSH utilization, and, can be applied to identify sensitive target tissues of toxicants.
- ||| Edecrin (ethacrynic acid) / Bausch Health, Henletor (torsemide) / Orchid, furosemide / Generic mfg.
Clinical: Oral dose equivalency (approximate) for patients with normal renal function: Torsemide 20 mg = bumetanide 1 mg = furosemide 40 mg = ethacrynic acid 50 mg (didn’t answer your question though!) (Twitter) - Feb 24, 2020
- | ethacrynic acid / Generic mfg.
Trial completion: Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection (clinicaltrials.gov) - Aug 22, 2017
P1, N=12, Completed, Sponsor: Eugene Lee, MD
MCB staining is a robust, sensitive method to detect spatiotemporal changes in GSH utilization, and, can be applied to identify sensitive target tissues of toxicants. Active, not recruiting --> Completed
- | ethacrynic acid / Generic mfg.
Enrollment closed: Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection (clinicaltrials.gov) - Feb 24, 2017
P1, N=12, Active, not recruiting, Sponsor: University of Kansas Medical Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | ethacrynic acid / Generic mfg.
Trial primary completion date: Novel Drug Delivery Technique Via Retroject Device (clinicaltrials.gov) - Feb 17, 2017
P1/2, N=9, Completed, Sponsor: Molly Walsh
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2016 --> Oct 2015
- ethacrynic acid / Generic mfg.
Enrollment open: Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection (clinicaltrials.gov) - Aug 31, 2016
P1, N=12, Recruiting, Sponsor: University of Kansas Medical Center
Trial primary completion date: Feb 2016 --> Oct 2015 Not yet recruiting --> Recruiting
- ethacrynic acid / Generic mfg.
New P1 trial: Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection (clinicaltrials.gov) - Aug 2, 2016
P1, N=12, Not yet recruiting, Sponsor: University of Kansas Medical Center
- ethacrynic acid / Generic mfg.
Trial completion, Enrollment change: Novel Drug Delivery Technique Via Retroject Device (clinicaltrials.gov) - Mar 17, 2016
P1/2, N=9, Completed, Sponsor: Molly Walsh
Not yet recruiting --> Recruiting Recruiting --> Completed | N=20 --> 9
- ethacrynic acid / Generic mfg.
Trial primary completion date: Novel Drug Delivery Technique Via Retroject Device (clinicaltrials.gov) - May 4, 2015
P1/2, N=20, Recruiting, Sponsor: Molly Walsh
Recruiting --> Completed | N=20 --> 9 Trial primary completion date: Dec 2014 --> Feb 2016
- ethacrynic acid / Generic mfg.
Enrollment open: Novel Drug Delivery Technique Via Retroject Device (clinicaltrials.gov) - Nov 24, 2014
P1/2, N=20, Recruiting, Sponsor: Molly Walsh
Trial primary completion date: Dec 2014 --> Feb 2016 Not yet recruiting --> Recruiting
- | ethacrynic acid / Generic mfg., furosemide / Generic mfg.
Trial completion, Enrollment change, Surgery: Furosemide Versus Ethacrynic Acid in Children With Congenital Heart Disease (clinicaltrials.gov) - Jul 24, 2014
P3, N=74, Completed, Sponsor: Bambino Gesù Hospital and Research Institute
Not yet recruiting --> Recruiting Recruiting --> Completed | N=106 --> 74
- ethacrynic acid / Generic mfg.
Trial initiation date: Novel Drug Delivery Technique Via Retroject Device (clinicaltrials.gov) - Apr 22, 2014
P1/2, N=20, Not yet recruiting, Sponsor: Molly Walsh
Recruiting --> Completed | N=106 --> 74 Initiation date: Jan 2014 --> May 2014
- ethacrynic acid / Generic mfg.
New P1/2 trial: Novel Drug Delivery Technique Via Retroject Device (clinicaltrials.gov) - Jan 29, 2014
P1/2, N=20, Not yet recruiting, Sponsor: Molly Walsh
- | ethacrynic acid / Generic mfg., furosemide / Generic mfg.
Trial initiation date, Surgery: Furosemide Versus Ethacrynic Acid in Children With Congenital Heart Disease (clinicaltrials.gov) - Dec 28, 2012
P3, N=106, Recruiting, Sponsor: Bambino Gesù Hospital and Research Institute
Initiation date: Jan 2014 --> May 2014 Initiation date: Jul 2012 --> Oct 2012
- | ethacrynic acid / Generic mfg., furosemide / Generic mfg.
Enrollment open, Surgery: Furosemide Versus Ethacrynic Acid in Children With Congenital Heart Disease (clinicaltrials.gov) - Dec 28, 2012
P3, N=106, Recruiting, Sponsor: Bambino Gesù Hospital and Research Institute
Initiation date: Jul 2012 --> Oct 2012 Not yet recruiting --> Recruiting
- || ethacrynic acid / Generic mfg., furosemide / Generic mfg.
New P3 trial, Surgery: Furosemide Versus Ethacrynic Acid in Children With Congenital Heart Disease (clinicaltrials.gov) - Jun 25, 2012
P3, N=106, Recruiting, Sponsor: Bambino Gesù Hospital and Research Institute